Baseimmune

Baseimmune is a London-based biotechnology company founded in 2019, specializing in the development of mutation-proof, universal vaccines and active immunotherapies for human and veterinary diseases.

The company utilizes a proprietary deep-learning AI platform to design synthetic antigens that remain effective against rapidly mutating pathogens. By combining computational modeling of pathogen evolution with advanced protein engineering, Baseimmune aims to address the challenge of "vaccine escape." Operating as a pre-clinical discovery-stage startup, Baseimmune collaborates with biotechnology and pharmaceutical partners through a B2B SaaS model. The company analyzes pathogen genomics, proteomics, and clinical data to generate tailored synthetic antigens. Its current pre-clinical programs target various diseases, including African Swine Fever, SARS-CoV-2, malaria, and chronic conditions like fibrosis. Baseimmune is committed to revolutionizing vaccine development by predicting future pathogen mutations and providing cross-protective solutions for healthcare providers and vaccine developers.